BioWorld

July 17, 2006

View Archived Issues

Patient Death In ConjuChem Phase II Trial Halts Dosing

ConjuChem Biotechnologies Inc. discontinued dosing in a Phase II trial of its growth hormone product, DAC:GRF in HIV lipodystrophy, pending an investigation into the death of a patient. (BioWorld Today) Read More

FDA Says Nastech's Calcitonin-Salmon Spray Not Approvable

Read More

Official 2006 List Of Buzzwords, Passé Terms, Fatigued Phrases

Read More

DeCode Stock Sale To Raise $30M For Multidrug Pipeline

Read More

Latest BioLineRx In-License: Oral Peptide Drug For Obesity

Read More

Other News To Note

Read More